Vitae Earns $14M from Boehringer Ingelheim with Start of Phase I Development
Alliance targets 11beta-HSD-1 for the treatment of metabolic syndrome disorders. Vitae Pharmaceuticals received a $14 million milestone payment from Boehringer Ingelheim with the initiation of a Phase I trial.…
Read guide →